Show simple item record

dc.creatorStanković, Dragana
dc.creatorRistić, Slavica M.
dc.creatorVukadinović, Aleksandar
dc.creatorMirković, Marija D.
dc.creatorVladimirov, Sandra S.
dc.creatorMilanović, Zorana
dc.creatorRadović, Magdalena
dc.creatorMijović, Milica
dc.creatorStanković, Dalibor M.
dc.creatorSabo, Tibor J.
dc.creatorVranješ-Đurić, Sanja
dc.creatorJanković, Drina
dc.date.accessioned2020-02-13T12:36:08Z
dc.date.available2020-02-13T12:36:08Z
dc.date.issued2019
dc.identifier.issn0960-3271
dc.identifier.urihttp://vinar.vin.bg.ac.rs/handle/123456789/8492
dc.description.abstractIt was reported that novel O,O′-diethyl-(S, S)-ethylenediamine-N,N′-di-2-(3-cyclohexyl) propanoate dihydrochloride (DE-EDCP) displayed in vitro antiproliferative activity on several human and mouse cancer cell lines, which was comparable to that of the prototypical anticancer drug cisplatin. In order to reveal its toxicity profile, acute and repeated-dose toxicity studies were performed in Naval Medical Research Institute (NMRI) Han mice. The intravenous LD50 values of DE-EDCP were found to be 95.3 and 101.3 mg/kg body weight in female and male mice, respectively. In the subacute toxicity study, DE-EDCP was administered intravenously at the doses of 15, 25, and 40 mg/kg/day for a period of 28 days. There were no adverse effects on general condition, growth, feed and water consumption, and hematological parameters. There was a significant increase in urea and alanine aminotransferase in female mice and aspartate aminotransferase and alkaline phosphatase in both genders in 40 mg/kg/day dose-treated group. The histopathological changes confined to the liver and kidney, but in other organs were not found. Satellite group revealed that changes in the kidney and liver were less pronounced, suggesting their reversibility. Interactions with DNA could also be of importance for understanding DE-EDCP toxic side effects. Hyperchromic effect obtained with ultraviolet–visible, suggested electrostatic interactions between DE-EDCP and calf thymus DNA. The toxicity testing of DE-EDCP was conducted to predict human outcomes. © The Author(s) 2018.en
dc.language.isoen
dc.relationinfo:eu-repo/grantAgreement/MESTD/Integrated and Interdisciplinary Research (IIR or III)/45015/RS//
dc.relationinfo:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/172035/RS//
dc.rightsrestrictedAccess
dc.sourceHuman & Experimental Toxicology
dc.subjectDE-EDCPen
dc.subjecttoxicity studyen
dc.subjectbiochemical analysisen
dc.subjecthematological parametersen
dc.subjectmiceen
dc.subjectDNA interactionen
dc.titleToxicity study of DE-EDCP as a potential drug for cancer therapy: Toxicity profile of DE-EDCPen
dc.typearticleen
dc.rights.licenseARR
dcterms.abstractМилановић, Зорана; Радовић, Магдалена; Мијовић, Милица; Јанковић, Дрина; Станковић, Драгана Т.; Ристић, Славица М; Вукадиновић, Aлександар A; Врањеш-Ђурић, Сања Д; Мирковић, Марија Д; Владимиров, Сандра С; Станковић, Далибор М; Сабо, Тибор Ј;
dc.rights.holder© The Author(s) 2018
dc.citation.volume38
dc.citation.issue4
dc.citation.spage466
dc.citation.epage481
dc.identifier.wos000462049400009
dc.identifier.doi10.1177/0960327118819047
dc.citation.rankM23
dc.identifier.pmid30558454
dc.type.versionpublishedVersion
dc.identifier.scopus2-s2.0-85060129792


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record